Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide in HTLV-1-associated myelopathy
IRCT20180618040127N3Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of teriflunomide in HTLV-1-associated myelopathy (HAM) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Serum TNF-alpha level, Serum neurofilament light level and 5 more. Started Jul 2021; status: completed.
02
Drugs
teriflunomide
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on IRCT20180618040127N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180618040127N3.